Omega 3 fatty acid supplementation after myocardial infarction: a systematic review and meta-analysis
BMC Cardiovascular Disorders - 2019
Tóm tắt
The purpose of this review is to examine the effect of Omega-3 Fatty acids on mortality, morbidity, and adverse events in patients with acute myocardial infarction (AMI). Data Sources: MEDLINE, EMBASE, and the Cochrane Library through May 2018. Study Selection: Randomized Controlled trials (RCT). Certainty of evidence was assessed with the GRADE system. Interventions: omega 3 fatty acids against placebo or no treatment. Primary and secondary outcomes: All-cause death, cardiovascular death, new AMI, stroke, need for therapeutic angioplasty or By-pass, new diagnosis of cancer and incidence of adverse events. For the efficacy endpoints we included 10 RCT (24,414 patients). Omega 3 fatty acids probably make little or no difference to all-cause mortality (4 studies 9141 patients RR 1.06 - CI95% 0.90 to 1.27, moderate certainty), cardiovascular mortality (3 studies 4304 patients RR 0.93 - CI95% 0.63 to 1.37, moderate certainty), new AMI (RR 1.24 CI95% 0.71 to 2.14 - moderate certainty), any cardiovascular event (RR 0.95 95%CI 0.86 to 1.05; low certainty due to risk of bias and imprecision), and stroke (RR 1.2 95%CCI 0,66–2,19 - moderate certainty). Regarding adverse events, we are uncertain if Omega 3 fatty acids improve/reduce non severe adverse events (RR 1.39 95% CI 0.36 to 5.34; very low certainty). There is probably little or no difference in the outcome suspension due to adverse events (RR 1.19 CI 95% 0.97 to 1.47; moderate certainty). For adult patients with AMI, omega 3 fatty-acids probably yield no benefit to patient important outcomes.
Từ khóa
Tài liệu tham khảo
Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism. 2004;53(2):153–8.
Foundation., B.N. n-3 fatty acids and health: briefing paper. London: British Nutrition Foundation; 1999.
Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract. 2003;57(4):305–14.
Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361:477–85.
Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212(1):252–9.
Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast eskimos. ActaMedicaScandinavica. 1972;192:85–94.
Bang HO, Dyerberg J, Hjorne N. The composition of food consumed by Greenland Eskimos. ActamedicaScandinavica. 1976;200:69–73.
CADTH - Grey Matters: a practical tool for searching health-related grey literature. https://www.cadth.ca/resources/finding-evidence/grey-matters. Accessed 5 May 2019.
National Center for Biotechnology Information. PubChem Compound Database; CID=446284. https://pubchem.ncbi.nlm.nih.gov/compound/446284. Accessed 5 May 2019.
University, C.G.a.M., Tools to assess risk of bias in cohort and case control studies; randomized controlled trials; and longitudinal symptom research studies aimed at the general population. 2013.
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol. 2011;64:1283–93.
Schünemann H, Brożek J., Guyatt G, Oxman A, GRADE handbook for grading quality of evidence and strength of recommendations. 2013.
Higgins JPT, Green S, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from https://training.cochrane.org/handbook.
National Center for Biotechnology Information. PubChem Compound Database; CID=5280934. https://pubchem.ncbi.nlm.nih.gov/compound/5280934. Accessed 5 May 2019.
Akl EA, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One. 2013;8(2):e57132.
Guyatt GH, Ebrahim S, Allonso-Coello P, Johnston BC, Mathioudakis AG, Briel M, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, Neumann I, Kahale LA, Iorio A, Meerpohl J, Schünemann H, Akl EA. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. J Clin Epidemiol. 2017;87:14–22.
Kromhout D, et al. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–26.
de Lorgeril M, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon diet heart study. Circulation. 1999;99(6):779–85.
Tuttle KR, et al. Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from the heart Institute of Spokane Diet Intervention and Evaluation Trial)††conflicts of interest: Dr. Bibus has received consulting fees from companies that make fish oil, Coromega co., vista, CA, and Enreco, Inc., Newton, WI. He also has equity ownership in lipid technologies, LLC, Austin, MN, the company that performed the plasma fatty acid analysis. Dr. Bibus owns patents related to lipid therapy. He has served as an expert witness regarding lipids and fatty acids. Am J Cardiol. 2008;101(11):1523–30.
Burr ML, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2(8666):757–61.
Borchgrevink CF, et al. Absence of prophylactic effect of linolenic acid in patients with coronary heart-disease. Lancet. 1966;2(7456):187–9.
Morris JN. Controlled trial of soya-bean oil in myocardial infarction, REPORT OF A RESEARCH COMMITTEE TO THE MEDICAL RESEARCH COUNCIL. Lancet. 1968;2(7570):693–9.
Marchioli R, et al. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lipids. 2001;36(Suppl):S119–26.
Nilsen DW, et al. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr. 2001;74(1):50–6.
Rauch B, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified Omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–9.
Singh RB, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. Cardiovasc Drugs Ther. 1997;11(3):485–91.
Heydari B, Abdulla S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffman U, Appelbaum E, Feng JH, Blankstein R, Steigner M, JP MC, Harris W, Antman EM, Jerosch-Herold M, Kwong RY. Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial. Circulation. 2016;134(5):378–91.
Grundt H , Nilsen DW, Hetland Ø, Mansoor MA. Clinical outcome and atherothrombogenic risk profile after prolonged washout following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr. 2004 Aug;23(4):491–500.
Smith J, Godlee F. Investigating allegations of scientific misconduct - Journals can do only so much; institutions need to be willing to investigate. BMJ. 2005;6:331–245.
C W. Suspected research fraud: difficulties of getting at the truth. BMJ. 2005;30(33):281–8.
Mercury Levels in Commercial Fish and Shellfish (1990-2012). https://www.fda.gov/food/metals/mercury-levels-commercial-fish-and-shellfish-1990-2012. Accessed 5 May 2019.
Hooper L, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease, in Cochrane Database of Systematic Reviews, C. The Cochrane. Chichester: John Wiley & Sons, Ltd; 2004.
Liem AKD, T.R. Dioxins: chemical analysis, exposure and risk assessment. 1st ed. Utrecht: Universiteit; 1997. (ISBN 90 393 2012 8)
UK., F.S.A., Dioxins and PCBs in the UK diet: 1997 Total diet study samples. Food Surveillance Information Sheet. 2000(Vol. 4/00. [ FSIS 4/00]).
Committee on toxicity of chemicals in food, consumerproducts and the environmentupdated - cot statement on a survey of mercury in fish and shellfish. https://cot.food.gov.uk/sites/default/files/cot/cotstmercuryfish.pdf. Accessed 5 May 2019.
Fernandes AR, Rose M, White S, Mortimer DN, Gem M. Dioxins and polychlorinated biphenyls (PCBs) in fish oil dietary supplements: Occurrence and human exposure in the UK. Food Addit. Contam. 2006;23:939–47.
Wen YT, Dai JH, Gao Q. Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24:470–475.
Aucoin M, Cooley K, Knee, Fritz Heidi, Balneaves GL, Breau R, Fergusson D, Skidmore B, Wong R, Seely D. Fish-Derived Omega-3 Fatty Acids and Prostate Cancer: A Systematic Review, Integr Cancer Ther. 2017;16(1):32–62. https://doi.org/10.1177/1534735416656052.
MacLean CH, Newbery SJ, Mujica WA, Issa A, Khanna P, Lim YW, et al. Effects of omega-3 fatty acids on cancer. Evidence Report/Technology Assessment. Rockville (MD): Agency for Healthcare Research and Quality; 2005. p. E010–2. Report No: 113(AHRQ Publication No: 05).
Galan P, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–30.
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.
Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD003177.
Kwak SM, MS, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (Eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172(9):686–94.
National Clinical Guideline, C. Myocardial infarction: cardiac rehabilitation and prevention of further MI NICE guidelines [CG172]. 2013.
Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16;113(19):2363–72.
Aung T, Halsey J,Kromhout D. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease RisksMeta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018;3(3):225-233. https://doi.org/10.1001/jamacardio.2017.5205.